Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Rating of “Buy” by Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $22.14.

A number of brokerages have commented on LXEO. Chardan Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research report on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Lexeo Therapeutics in a research note on Thursday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th.

Lexeo Therapeutics Trading Up 0.4 %

LXEO stock opened at $7.93 on Friday. Lexeo Therapeutics has a 1-year low of $7.54 and a 1-year high of $22.33. The firm has a market cap of $262.17 million and a P/E ratio of -0.54. The business’s 50 day moving average is $9.71 and its 200-day moving average is $12.54. The company has a current ratio of 9.38, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting analysts’ consensus estimates of ($0.64). Equities analysts anticipate that Lexeo Therapeutics will post -2.76 earnings per share for the current fiscal year.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $1,285,401.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 15,000 shares of company stock worth $151,400. Insiders own 4.50% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. bought a new stake in shares of Lexeo Therapeutics during the 1st quarter valued at $10,364,000. Janus Henderson Group PLC boosted its holdings in shares of Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock worth $39,802,000 after purchasing an additional 210,047 shares in the last quarter. Artal Group S.A. boosted its holdings in shares of Lexeo Therapeutics by 32.9% in the 1st quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after purchasing an additional 198,281 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after purchasing an additional 65,573 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in Lexeo Therapeutics during the 3rd quarter valued at about $67,000. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.